Efficacy of Cognitively-based compassion training for Veterans with chronic pain with psychological Comorbidity: Protocol for a randomized clinical trial Authors: Anne Malaktaris, Niloofar Afari, Pollyanna Casmar, Matthew S Herbert, Rachel Raver, Julie Kangas, Lin Liu, Fadel Zeidan, Ariel J Lang Published: 2026 ABSTRACT AbstractChronic pain with psychological comorbidity, especially posttraumatic stress disorder (PTSD) and/or depression, is a prevalent and costly problem, especially among Veterans. Compassion meditation (CM) is a meditative practice that focuses on developing attentional regulation and the intention to assuage suffering. CM-based approaches show promise in ameliorating physical and mental health problems as well as improving quality of life. The objective of this study, a randomized clinical trial, is to compare the efficacy of Cognitively-Based Compassion Training® for Chronic Pain with Psychological Comorbidity (CBCT-CP+) to Health Education while Living with Pain (H.E.L.P.; health psychoeducation control), among 142 Veterans with chronic pain and psychological comorbidity (PTSD and/or depression). Veterans in both groups will participate in 10 weekly, 90-min virtual group sessions, and will be assessed at baseline (0 weeks), weekly during intervention (weeks 1-10), mid-treatment (between weeks 4 and 5), posttreatment (10 weeks), 3-month and 6-month follow-up. The primary aim is to evaluate the efficacy of CBCT-CP + compared to H.E.L.P. in reducing 1) pain interference (measured with Brief Pain Inventory (BPI)) and 2) severity of comorbid psychopathology (PTSD and/or depression; assessed with the Clinical Global Impression scale (CGI)). We hypothesize that CBCT-CP + will be associated with larger reductions in pain interference and severity of comorbid psychopathology (co-primary outcomes) compared to control. We also hypothesize that CBCT-CP + will be associated with greater improvements in life satisfaction and quality of life (secondary outcomes). If efficacious, CBCT-CP + could be further evaluated via multi-site or hybrid effectiveness trials and, ultimately, could improve treatment outcomes for Veterans with chronic pain (CP) and PTSD and/or depression. This randomized clinical trial is registered at clinicaltrials.gov (ID: NCT04651296).Keywords: Chronic pain, Posttraumatic stress disorder, Depression, Randomized clinical trial, Compassion meditation United States military Veterans frequently experience chronic non-cancer pain (CP), defined as persistent, non-malignant pain lasting for 6 or more months [1]. Specifically, 30-40% of Veterans experience moderate to severe CP [2,3], a complex, multidimensional experience with deleterious impacts on mental health and quality of life, including declines in functioning and decreased activity levels [4,5]. Pain-related impacts on functioning (physical, occupational, and social) and enjoyment of life are often collectively defined as pain interference, which has emerged as an important outcome of interest [6]. Pain interference is distinct from pain intensity (overall pain severity/magnitude). High levels of pain interference are predictive of poorer psychological functioning [7] and poorer health outcomes, including overall mortality [8]. CP is often accompanied by mental health conditions, including posttraumatic stress disorder (PTSD) and depression; 1.5 to 2 million Veterans Health Administration-enrolled Veterans with CP have a psychological comorbidity, including PTSD (∼50%) or depression (∼25%) [9]. Psychological comorbidities are associated with higher healthcare utilization, medication use, and incidence of medication-related adverse events [[9], [10], [11]] compared to those with one condition. Numerous studies have examined the association between pain interference and psychological comorbidity, especially PTSD, in an attempt to explain the nature and direction of comorbidity, including risk factors and psychological correlates [[12], [13], [14], [15], [16]], and several theoretical models of comorbidity have been proposed, including the Mutual Maintenance model [12,13] the Shared Vulnerability model [12], the Diathesis-Stress model [14,16], and the Perpetual Avoidance model [15]. There are currently no evidence-based psychosocial interventions that simultaneously target CP interference and common psychological comorbidities in Veterans. Usual care for CP with psychological comorbidity is often poorly integrated, and gold standard interventions, which are generally disorder-specific, do not always confer desired benefits. For example, some studies of cognitive behavioral therapy for chronic pain (CBT-CP) have found that psychological comorbidities, including depression, have been associated with poorer treatment response [17], and that other psychological characteristics, such as psychological inflexibility and rumination may further worsen CBT-CP outcomes [18,19]. However, other studies have found that the co-occurrence of PTSD did not interfere with CBT-CP [20]. Further, although specific cognitive behavioral therapies (CBTs) are considered gold standard treatments for PTSD and depression, as many as 30-50% of patients drop out or do not complete disorder-specific CBTs [[21], [22], [23], [24]]. This pattern is similar among military Veterans, where remission rates of PTSD in military Veterans remain disappointing, even among those receiving gold standard treatments (e.g., 60-70% of Veterans retained PTSD diagnoses after completing trauma-focused, evidence-based psychotherapy) [25]. Thus, Veterans with CP and psychological comorbidities would greatly benefit from innovative interventions, including complementary and integrative health (CIH) approaches. CIH approaches, which include meditation, are frequently used among Veterans with CP and PTSD [26], and more than half of Veterans (53.2%) reported using CIH approaches. However, the lack of large-scale randomized trials precludes inferences about efficacy of CIH approaches. Well-designed, randomized efficacy studies are needed to further understand potential benefits. Compassion meditation (CM; a practice for cultivating compassion for self and others that focuses on the wish to remove suffering) has shown promise in improving mental and physical health problems and quality of life and may target factors implicated in theoretical models of CP with PTSD and/or depression comorbidity. For example, our preliminary work suggests increases in positive emotion, which have been associated with enhancements in coping and resilience [27], are facilitated by practice of compassion meditation among Veterans with PTSD [28]. CM includes the practice of mindfulness, which has been associated with diminished physiological arousal and increased acceptance of difficult experiences [29]. Increases in mindfulness have in turn been associated with improvements in PTSD and depression in Veterans [30]. Increased self-compassion has also been associated with reduced pain catastrophizing and pain interference among individuals with CP [31]. Finally, there is some evidence that CM may promote pain acceptance [32,33], which is predictive of pain interference [33]. To summarize, CM-based approaches cultivate mindfulness, positive emotions, and social connectedness, which in turn have positive effects on processes that support recovery from CP with psychological comorbidity (e.g., pain acceptance, catastrophizing). The joint effect is reduced severity of comorbid psychological symptomatology, and improved chronic pain-related functioning and well-being. See Fig. 1 for theoretical model of recovery. Theoretical model of recovery. There are several specific manualized protocols that emphasize CM as a core intervention element (CM-based approaches). Among adults with CP, CM-based approaches were associated with reductions in psychological distress, pain severity, pain-related functional interference, pain-related anxiety and depression, and pain-related anger as well as increases in self-compassion, pain acceptance, and psychological flexibility [[34], [35], [36]]. One randomized controlled trial (RCT) compared Mindful Self-Compassion (MSC) to CBT among individuals with CP [37] and found that MSC was superior to CBT across outcomes, including pain interference and intensity, anxiety and depression symptom severity, quality of life and pain catastrophizing and acceptance. A recent meta-analysis found that CM-based approaches are associated with improvements in compassion for others, self-compassion, mindfulness, depression, anxiety, psychological distress, and well-being, and these effect sizes were medium [38]. Cognitively-Based Compassion Training (CBCT©) [39], a manualized CM-based approach, has shown promise in various clinical populations. A proof-of-concept and feasibility study of CBCT for Veterans with PTSD (CBCT-Vet) demonstrated feasibility (e.g., adequate recruitment/retention, Veterans’ ratings of credibility and satisfaction) [28,40]. Among thirty-seven Veterans with PTSD randomized to CBCT-Vet vs. relaxation control, there was a clinically meaningful reduction in the CBCT-Vet group in PTSD and depression symptom severity (large effect sizes, ESs), whereas such changes were not observed in the control group (small ESs) [28]. In a separate study, CBCT was associated with reductions in depressive symptoms and suicidal ideation among individuals with history of suicide attempt(s) [41]. Further, in an RCT of CBCT vs. control among individuals with HIV, CBCT was associated with greater reductions in inflammation and psychological stress [42]. Finally, CBCT was compared to treatment-as-usual in an RCT among breast cancer survivors; CBCT was effective in reducing distress related to fear of cancer recurrence and in increasing self-compassion and mindfulness skills [43]. Less is known about the potential benefits of CBCT and its various adaptations among individuals, including Veterans, with CP with psychological comorbidities (PTSD and/or depression). In sum, there are no established integrated interventions for CP with comorbid PTSD and/or depression, and Veterans with CP with PTSD and/or depression have different needs than those with one condition. CIH approaches, which are transdiagnostic, may address these simultaneously. CM-based approaches, including CBCT, have been associated with improvements in pain and PTSD and/or depression-related outcomes. As noted in recent critical reviews [26], many previous studies of CM-based approaches were not conducted with clinical samples, were small, underpowered, and/or non-randomized studies, or did not include well-designed control conditions. This study aims to bridge the existing evidence gap regarding the efficacy of a new adaptation of CBCT among Veterans with CP with psychological comorbidity (PTSD and/or depression). Materials and methods Research design The objective of this randomized clinical trial (RCT) is to evaluate the efficacy of Cognitively-Based Compassion Training® for Chronic Pain with Psychological Comorbidity (CBCT-CP+) compared to Health Education while Living with Pain (H.E.L.P.), among Veterans (N = 142) with CP and psychological comorbidity (PTSD and/or depression). We will evaluate primary, secondary, and exploratory measures at baseline (0 weeks), mid-treatment (between weeks 4 and 5), posttreatment (10 weeks; primary endpoint), and 3- and 6-month follow-up with weekly data collection of symptom severity/safety measures during active treatment (weeks 1-10). This study will follow the Consolidated Standards of Reporting Trials (CONSORT) reporting guidelines. See Fig. 2 for projected study participant flow. Pain interference and severity of comorbid psychopathology (PTSD and/or depression) are our co-primary outcomes (i.e., two equally important outcomes). Our specific aims are as follows: CONSORT 2025 flow diagram. Aim 1 (co-primary treatment outcomes): evaluate the efficacy of CBCT-CP + compared to H.E.L.P. in reducing 1) pain interference (measured with Brief Pain Inventory (BPI), Pain Interference subscale) [2,44]) severity of comorbid psychopathology (PTSD and/or depression; assessed with the Clinical Global Impression scale (CGI)) [45]. Aim 2 (secondary treatment outcomes): evaluate the efficacy of CBCT-CP+, when compared to control group (H.E.L.P), in improving life satisfaction (measured with Satisfaction with Life Scale) [46] and health-related quality of life (measured with the Veterans SF-36) [47]. Exploratory Aim 3 (mediation): to examine potential psychological mechanisms of treatment response including positive emotions, social connectedness, mindfulness, compassion, pain coping, pain-related anxiety, and pain acceptance. Exploratory Aim 4 (exploratory outcome measures and moderators): to investigate exploratory outcomes including suicidal ideation, alcohol or opioid misuse, and insomnia severity and potential moderators of treatment effects including patient factors (e.g., symptom severity, pain intensity) and other factors (sessions completed, duration of homework completed). Participants and sample size Study participants will be US military Veterans with CP with psychological comorbidity (depressive disorder and/or PTSD). Inclusion criteria will be as follows: (1) Veteran status, (2) age 18 or greater, (3) able to consent, and (4) diagnosis of any chronic, non-terminal pain condition (per medical chart and/or self-report), (5) pain most days (>3 days/week) for at least 6 months (per self-report), (6) average pain severity and interference rated ≥4/10 over the past week (as measured by the Pain, Enjoyment of life, General activity Scale, PEG) [48], and (7) diagnosis of depression and/or PTSD based on the Mini International Neuropsychiatric Interview (MINI 7.0) [49]. Exclusion criteria will be as follows: (1) serious suicidality or homicidality that has required urgent or emergent evaluation or treatment within the past three months or a suicide attempt within the past year, (2) a known, untreated substance use disorder, (3) untreated/unstable serious mental disorders, such as psychotic disorders, bipolar disorder, or serious dissociative symptoms, (4) cognitive impairment that would interfere with treatment, and (5) concurrent enrollment in other psychotherapy (individual or group) specifically targeting CP, depression, PTSD symptoms, or social functioning or any meditation-based interventions, including CM-based approaches. Participants will be permitted to continue current medications. Finally, participants can continue with concurrent supportive or nonspecific therapy. The target N was chosen based on the power estimations for an intent-to-treat design and accounts for nested design (group treatment). The power analysis was performed using G∗power statistical software. We estimated a final sample size of N = 96 needed to detect large effect size (d = .8) in co-primary outcomes, 1) pain interference (measured with BPI-PI) and 2) severity of comorbid psychopathology (assessed with the Clinical Global Impression scale, CGI). An effect size of d = .8 for changes in pain interference is based on a previous study [36] of a CM-based approach vs. relaxation control in a CP sample, which yielded large between groups effect sizes on changes in pain interference pre-to posttreatment. An effect size of d = .8 for changes in severity of comorbid psychopathology is based on a previous study [28] of CBCT-Vet vs. relaxation control for Veterans, which yielded large between groups effect size. Although our previous studies yielded non-significant group level treatment effects, we have still accounted for the nesting within our data and estimated our effective sample size using a small intra-class correlation (ICC). We accounted for a small within subjects ES for non-specific effects of H.E.L.P. The significance level (α) for co-primary outcomes is divided by two (α = .025) to protect against Type I error and correct for multiple comparisons. In order to achieve our final sample of N = 96, we will screen N = 190, allowing for approximately 25% (n = 48) ineligibility/decline to participate, yielding our targeted N = 142 enrolled/randomized. We have also conservatively accounted for 32% (n = 46) post-randomization withdrawal. Study procedures All procedures will be performed in compliance with relevant laws and institutional guidelines and were approved on 10/21/20 by the Institutional Review Board (IRB) at VA San Diego Healthcare System (H200100). Written informed consent will be obtained from all participants. Potential participants will be recruited primarily from outpatient mental health clinics at the VA San Diego Healthcare System via provider and self-referral. Veterans who express interest will be invited to schedule a virtual appointment for evaluation of eligibility and baseline assessment. Eligible participants will be randomized to compassion meditation protocol (CBCT-CP+) or a health and wellness psychoeducation control condition (H.E.L.P.). Approximately 4-10 Veterans will be randomized to each group cohort. See Fig. 3 for timeline of interventions and assessments. Timeline of interventions and assessments. Note: The data collection for primary and secondary outcomes occurs baseline, mid-treatment (between session 4 and 5), posttreatment (after session 10), 3-month follow-up, and 6-month posttreatment follow-up with weekly data collection of symptom severity/safety measures during active treatment (weeks 1-10). We will use multiple strategies to encourage participant retention. We will implement a “Treatment Expectations Session” (see Interventions). Participants will receive regular appointment reminders. Veterans will attend appointments virtually, which can remove potential barriers to engagement. Group cohesion will be encouraged by facilitating discussion of shared experiences and challenges of learning new CIH approaches. Finally, study staff will conduct weekly check-in phone calls during intervention phase to address challenges to engagement and encourage protocol adherence. Safety monitoring We will exclude individuals with serious suicidality or homicidality. Study staff will conduct weekly check-ins via telephone and will complete weekly electronic health record reviews during intervention to monitor for changes in health, possible adverse events, suicidal ideation, and clinically significant worsening of symptoms. Weekly symptom questionnaires will also be administered electronically during active treatment phase (weeks 1-10). Crisis intervention and transfer/admission to a higher level of care will be provided if needed. Interventions Cognitively-based compassion Training® for chronic pain with psychological comorbidity (CBCT-CP+) Our CBCT-CP + protocol is a new adaptation of Cognitively-Based Compassion Training [39] for Veterans with chronic pain and comorbid PTSD and/or depression. CBCT-CP+ was refined over the course of several years, based on clinical experience and pilot studies [28,40] and Veteran feedback and input from other Veterans Health Administration (VHA) stakeholders and subject-matter experts. The core intervention of CBCT-CP+, compassion meditation, is a secularized, transdiagnostic practice derived from the lojong tradition of Tibetan Buddhism. The Veteran-specific modifications include use of language at 8th grade reading level, examples from military culture, and instruction in behavioral changes that apply lessons from meditation to daily life. The pain- and comorbidity-related modifications include adding pain-specific instructions for meditation and pain psychoeducation. CBCT-CP + consists of 10 weekly, 90-min group sessions, which are reinforced by daily guided meditation recordings and behavioral homework. Each CBCT-CP + session includes a review of homework and previous topics, experiential exercises and discussions of a new treatment topic, and formal seated meditation practice [50]. Formal meditation practices are explicitly linked with present-moment contact, non-judgment, self-compassion, equanimity, interdependence, gratitude and engaged compassion (see Table 1). Meditation skills are taught in an iterative fashion, and are reinforced with in-session experiential exercises, as well as at-home practice. Table 1Session topics and content details of the CBCT-CP+ and H.E.L.P. Group manualized protocols.Table 1Session NumberCBCT-CP + TopicCBCT-CP + DetailsH.E.L.P. TopicH.E.L.P. Details1Introduction to CBCTbrief overview of the 10 group sessions; basic breathing meditation; rationale for CBCTIntroduction to Health and Wellnessmeaning of health and wellness, how it relates to personal health concerns, and the relationship between health domains2Focusing Attentionbenefits of attending to the breath; address common misconceptions about getting rid of thoughts and emotions; research outcomes of meditation studiesBasics of Good Nutrition and Healthy Eatingbenefits and barriers to healthy eating and suggestions for healthy diets3Creating Spacepractice present moment focused awareness; use sensory distractions to heighten their attention instead of continuing to tie their attention to the breathGetting Better Sleepbenefits and barriers to good sleep, the relationship between pain and sleep, and recommendations for good sleep4Mindful, Open, and Aware: Relax the Rulescontinued practice on present moment focused awareness; mindful listening to a partner in classRelaxationbenefits of relaxation, interference of breathing problems on deep breathing, and introduce relaxation activities5Re-Engaging Heroic Spiritintroduction of positive cognitive reflection; even superheroes have flaws; perfectionism and self-blame are barriers to self-awareness and compassionPhysical Activity/Exercisebenefits and barriers to physical activity, suggestions for adapting physical activity, and safe exercise practices6Seeing Ourselves in Othersall beings want to avoid suffering and find satisfaction in life; behavior and not humanity can be inappropriate; begin building a more open acceptance of othersTobacco, Alcohol, and Drug Usepatterns of nicotine and alcohol use, how they relate to physical and mental health, and strategies for promoting moderation7Appreciation & Gratitudecreate an awareness of interdependence and build appreciation and gratitude for the human familyMedication and Side Effectsvarious purposes of medication, barriers to safe medication use, dangers of misuse, side effects, and suggestions for taking medications as prescribed8Empathy and Engaged Compassionall people have bad habits; change is difficult for all people; build the wish to relieve suffering for othersStress Management and Moodimpact of stress on mental and physical health, suggestions for introducing pleasant activities, and incorporating social support and problem-solving strategies9Review, Meditating without Recordingsreview and relapse prevention session; create meditation cards to keep for instant coping; personalized meanings of the sessions are shared among membersCommunication and Talking to Medical Providerscommunication barriers and strategies on topics of chronic pain and mental health with loved ones sand health care providers10Putting it all Togethercreate coping cards for applying meditation in everyday actions; review completed homework; lessons on how to avoid compassion fatigue and continue to build positive emotionsSocial Support and Closingrelevance of social support on health and wellness, identify sources of support, and suggestions for expanding support network. Review previous topics Session topics and content details of the CBCT-CP+ and H.E.L.P. Group manualized protocols. Health education while living with pain (H.E.L.P) The Health Education while Living with Pain (H.E.L.P.) protocol was based on related health-related psychoeducation groups but does not include motivational interviewing/enhancement, behavior change/health coaching strategies, or goal setting [50]. As such, H.E.L.P. is expected to have minimal impact on the clinical outcomes or potential mechanisms (e.g., mindfulness, pain acceptance) of interest. H.E.L.P. matches CBCT-CP+ in length of group meetings, provider involvement, social interaction with group members, psychoeducation, homework assignments, and weekly follow-up telephone calls. H.E.L.P. consists of 10 weekly, 90-min sessions featuring didactics and group discussion of health and wellness topics relevant to Veterans with chronic pain and psychological comorbidity (e.g., Nutrition/Healthy Eating, Tobacco, Alcohol, and Substance use, Stress Management; see Table 1 for additional details). H.E.L.P. is informational only and does not include any specific prescription of behavioral goals or strategic skills practice. Instead, H.E.L.P. homework assignments include hand-outs, informational videos, and questions about content comprehension. Therapy expectations session Prior to group randomization, all eligible participants will attend the group therapy expectations session. This session was developed to provide an orientation to telehealth, enhance motivation, and problem-solve any potential barriers to engagement. Veterans are led in discussion of their reasons for coming into treatment, goals for engaging in treatment, expectations for CIH approaches, and potential barriers to treatment. Randomization Following therapy expectations session, eligible groups of participants will be randomized to one of two intervention conditions (CBCT-CP + or H.E.L.P.) based on a computer-generated randomization table prepared prior to the start of the study by the study biostatistician. Groups of 4-10 (expected to average n = 7) will be randomized with 1:1 allocation to CBCT-CP+ and H.E.L.P. To maximize feasibility of recruitment and retention and reduce wait-times, we will not use block randomization or stratification (based on pain interference, severity of comorbid psychopathology). It is expected that randomization will balance out pain interference and severity of comorbid psychopathology, and this will be assessed in analyses. Randomization will occur after maximum group size is achieved (n = 10) or after 6 weeks of enrollment have elapsed, whichever occurs first. Allowing for variable group size increases feasibility of initiation/retention by reducing wait times and accommodating for variability in rates of (self-)referral across the intervention phase. Study personnel involved in screening/enrolling participants will be blinded to group assignments. Intervention procedures We will conduct all study activities, including both group CBCT-CP+ and H.E.L.P. sessions, using VA-approved telehealth technology. Instructors for CBCT-CP + M groups will be trained in CBCT using the Emory Intensive Teacher Training Program. The training intensive is open to the general public and is led by Dr. Lobsang Negi, a long-term contemplative investigator and former Buddhist monk. H.E.L.P. instructor(s) will be trained in Health Education while Living with Pain via intensive review of the treatment manual with demonstration of in-class didactics. The principal investigator and co-investigators (P.C. and A.J.L.) will provide training, consultation, and supervision (if applicable) in implementing CBCT-CP+ and H.E.L.P. among Veterans with CP with PTSD and/or depression. We developed a fidelity tool to assess a) unique and essential elements of each approach, (b) essential features that are not unique (e.g., warmth), and (c) proscribed elements (e.g., features other common interventions), as well as a general appraisal of the session. We will randomly select 10% of all group sessions for fidelity review. Fidelity assessments will be conducted by principal investigator and co-investigators (P.C. and A.J.L.). Measures Data will be collected at baseline, mid-treatment (between session 4 and 5), weekly (during active treatment, weeks 1-10), posttreatment (after session 10), 3-month follow-up, and 6-month posttreatment follow-up assessments. See Table 2 for assessment schedule details. We will conduct all data collection using VA-approved telehealth technology. Clinician-administered interviews will be conducted using videoconferencing (telephone/audio only as back-up). All self-report measures will be completed using secure fillable PDFs and returned via approved methods (e.g., secure messaging). Table 2Assessment details.Table 2Assessment MeasureBaselineMid-TreatmentBiweekly During InterventionPost-treatment3 mo. Follow-Up6 mo. Follow-UpEligibility MeasuresPEGXMINIXMoCAXPrimary and Secondary Outcome MeasuresBPIXXXXXCGIXXXXCAPS-5XXXXHAM-DXXXXSWLSXXXXXSF-36XXXXXExploratory Measures of Potential MediatorsCSQ-RXXXXPASS-20XXXXCPAQXXXXPANASXXXXSCS-RXXXXFMIXXXXCSXXXXExploratory Outcome/Safety MeasuresISIXXXXCSSR-SXXXXAUDIT-CXXXXPMQXXXXPHQ-9XXXXPCL-5XXXXGAD-7XXXX Assessment details. At baseline, we will collect socio-demographic and background information [51] including participants’ age, gender, race, ethnicity, relationship status, years of education, income, living situation, occupation, work status, combat deployment, branch of service, and highest rank. Measures to determine eligibility During eligibility evaluation, we will administer the PEG scale [48], a brief screening tool, to screen for the presence of chronic non-cancer pain (e.g., musculoskeletal pain, neuropathic pain, chronic headaches). Specifically, the PEG has three items assessing pain intensity (P), interference with enjoyment of life (E), and interference with general activity (G). Veterans will be screened for PTSD and/or depression diagnosis with the MINI 7.0 [49], a clinician-administered interview which has been validated against other established clinical interviews and updated for DSM-5. Diagnostic profile, including untreated/unstable serious mental disorders, such as psychotic disorders or bipolar disorder, or serious dissociative symptom (exclusion criteria 3), and suicide risk will also be established using the MINI, which will be supplemented with questions to assess homicidality. We will assess cognitive impairment (exclusion criteria 4) using the Montreal Cognitive Assessment (MoCA-Blind) [52,53], a brief, clinician-administered cognitive screening suitable for telehealth administration. Participants with MoCA-Blind score <18 will be referred for additional evaluation and excluded unless a qualified clinician provides clearance to participate. Co-primary outcomes Pain interference will be measured with Brief Pain Inventory (BPI), Pain Interference subscale [44]. The BPI Pain Interference subscale consists of 7 items assessing the degree to which pain functionally interferes with life, including mobility, social activities, and mood. The severity of comorbid psychopathology (PTSD and/or depression) will be assessed with the CGI [45]. The CGI consists of two one-item, clinician-rated measures assessing 1) the severity of psychopathology from 1 (normal, not at all ill) to 7 (among the most extremely ill patients), CGI-S, and 2) the improvement in functioning since baseline assessment from 1 (very much improved) to 7 (very much worse), CGI-I. The CGI is a well-established measure of psychological symptom severity and has been validated against gold-standard disorder-specific interviews [54,55]. The CGI has good internal consistency and concurrent validity [56]. The Clinician Administered PTSD Scale (CAPS-5) [57,58] and Hamilton Rating Scale for Depression (HAM-D) [59] will be used to inform the CGI ratings, describe the sample, and perform disorder-specific sub-group analyses. The CAPS-5 [57,58] is the gold-standard clinician-administered interview to establish PTSD diagnosis and quantify symptom severity, and the CAPS-5 has well-established internal consistency and validity. The HAM-D is the gold-standard rating clinician-administered interview of depression with adequate reliability and validity. The HAM-D will be administered using a structured interview guide [60]. The CAP-5 and the HAM-D yield diagnoses and severity scores for PTSD and depression, respectively. Independent study assessors will be licensed independent providers or unlicensed clinicians with appropriate supervision and will complete CAP-5 and/or HAM-D and CGI ratings while remaining blind to treatment conditions. Secondary outcomes Secondary clinical outcomes, life satisfaction and health-related quality of life will be assessed with the Satisfaction with Life Scale (SWLS) [46] and the Veterans RAND 36-Item Health Survey (Veterans SF-36) [47], respectively. The SWLS is a 5-item self-report measure of global life satisfaction. The Veterans SF-36, is a widely-used, reliable, and valid self-report measure, which yields a physical component summary (PCS) and a mental component summary (MCS) [47,61]. Exploratory measures Potential mediators We included a variety of measures intended to explore potential mediators of treatment response based on our theoretical model of recovery [[62], [63], [64]] and previous studies [[65], [66], [67]]. We will measure coping among pain patients using the revised Coping Strategies Questionnaire (CSQ-R) [68,69]. The CSQ-R has 27 items assessing six domains of coping strategies: distraction, catastrophizing, ignoring pain, distracting from the pain, coping self-statements, and praying. Fearful and anxious responses to pain will be evaluated using the 20-item Pain Anxiety Symptoms Scale (PASS-20) [70]. The PASS-20 has good psychometric properties, including internal consistency, reliability, and construct validity. Pain acceptance will be measured with the Chronic Pain Acceptance Questionnaire (CPAQ) [71], a measure consisting of 20 items rated on a 7-point Likert scale. The CPAQ yields two subscales, activity engagement and pain willingness, and has good psychometric properties. Finally, pain severity will be measured with the 4-item BPI Pain Severity subscale [44]. We will measure positive and negative emotions with the 20-item Positive and Negative Affect Scale (PANAS) [72]. Social connectedness will be assessed with the 20-item self-report Social Connectedness Scale – Revised (SCS-R) [73]; the SCS-R has good psychometric properties (e.g., internal consistency, convergent and divergent validity). We will measure self-reported mindfulness with the 14-item Freiburg Mindfulness Inventory (FMI) [74], a well-established measure of mindfulness with good reliability and validity in psychiatric populations. Finally, we will measure compassion for others with the 16-item Compassion Scale (CS) [75]. The CS has strong psychometric properties. Exploratory/safety measures Insomnia severity will be assessed with the 7-item Insomnia Severity Index (ISI) [76]. The ISI has good reliability and convergent validity and is sensitive in detecting clinical insomnia [77]. We will explore changes in suicidal ideation with the Columbia–Suicide Severity Rating Scale (C–SSRS) [78]. The C–SSRS is a semi-structured interview that prospectively evaluates suicidal ideation and behavior. We will explore severity and intensity of ideation subscale scores. The C–SSRS has good convergent, divergent, and predictive validity and sensitivity to change [78]. We will assess problematic alcohol use with the 3-item Alcohol Use Disorders Identification Test (AUDIT-C) [79]. We will measure the risk for opioid misuse with the 27-item Pain Medication Questionnaire (PMQ) [80]; the PMQ has good psychometric properties. Depression symptom severity will be assessed with the Patient Health Questionnaire 9-item (PHQ-9) [81]. PTSD symptom severity will be measured with the 20-item PTSD Checklist for DSM-5 (PCL-5) [82,83]). Finally, anxiety symptoms will be measured with the Generalized Anxiety Disorder 7-item scale (GAD-7) [83]. Adherence and medication information We will assess adherence to treatment with homework journals completed daily by participants.; Specifically, Veterans will report time spent per week on meditation practice (CBCT-CP+) or health education (H.E.L.P.). Daily homework journals (completed electronically or via paper and pencil) for the previous week will be collected by telephone or secure electronic return before each group meeting. Basic medication information (names and start dates of current medications) will be collected at the baseline, posttreatment, and follow-up assessments [51]. Data analytic plan Preliminary analyses Upon completion of data collection, our preliminary analyses will include descriptive statistics of the study sample, variable distributions and outliers, including examination of modeling assumptions, internal consistency and reliability of scales, and between groups differences at baseline in sociodemographic characteristics (e.g., age, sex) and concomitant medication use. Age, sex, race, and ethnicity have been pre-specified as covariates based on other studies demonstrating their associating with pain interference [84]. The preliminary analysis will be used to inform which additional covariates, including other baseline demographics and other clinically important baseline characteristics, should be entered while building models for testing the study hypotheses. For each model below, a variable that is significantly associated with either outcome (pain interference, severity of comorbid psychopathology) or predictor (comparison groups: CBCT-CP + or H.E.L.P.) will be added as a potential covariate and variables with p value < .05 were considered as potential covariates in final models. Missing data We will attempt to minimize missing data during data collection. We will examine any missing data to assess randomness, including comparing group differences in the primary outcomes of participants with versus without missing data. Analyses of primary and secondary outcomes Analyses of primary and secondary outcomes will be conducted using random effects models (also known as hierarchical linear models, Linear Mixed Effects models or multilevel models). Random effects models allow for the inclusion of subjects with missing data without relying on data imputation procedures. This method provides an estimate of the individual variability around the population trend, the variability of the individual intercepts (baseline values) and slopes (changes across time), and the correlation between them. The random effects models for co-primary outcomes, pain interference (BPI) and severity of comorbid psychopathology (CGI-S), will include a random intercept, a random slope for assessment time, fixed effects for comparison groups (CBCT-CP+, H.E.L.P.), assessment time, and group-by-time interaction. The significance of random slope for time will be assessed using a likelihood ratio test; if it is not significant, we will consider a random intercept model only. Since the intervention will be delivered in groups, we will consider random group level treatment effects for importance based on the likelihood ratio test or the model AIC (Akaike's Information Criterion), where appropriate, and will incorporate group level effects into the model if needed. The normal assumption of model residuals and random effects will be assessed, and transformation of outcomes such as log transformation and sensitivity analysis by excluding outliers will be considered if the assumption is violated. We will use an intent-to-treat approach, where data will be included from all randomized subjects using all available data. We will calculate between groups pre-to posttreatment effect sizes, and these effect sizes will be interpreted in the context of the 95% confidence interval (CI) that surrounds them. Analyses of primary outcome measures at the 6-month follow-up will be exploratory and will be conducted using the analyses described above. Analyses of secondary outcome measures will likewise be conducted using the same procedures as the primary outcome measures. Analyses of mechanisms of treatment effects Analyses of treatment mediators will be conducted using the same random effects models as in Aim 1. For the model of pain interference (BPI interference subscale scores), pain coping (CSQ-R), pain-related anxiety (PASS-20), and pain acceptance (CPAQ) will be added to the model as covariates. Likewise, for the model of severity of comorbid psychopathology (CGI-S scores), at each time point, positive emotions (PANAS), social connectedness (SCS-R), mindfulness (FMI), and compassion (CS) will be added to the model as covariates. To ensure meaningful interpretation, we will include the mediators assessed at mid-treatment and the outcomes assessed at posttreatment. Analyses of exploratory outcomes and moderators Our exploratory outcome measures and moderators will be analyzed in the same way as Aims 1 and 2. An interaction between potential moderators and treatment will be included in the model to assess the moderator effect. Discussion CIH approaches, such as CM, have generated sustained enthusiasm for their potential benefits, including among Veterans with CP and psychological comorbidities. We have described the study protocol for this RCT, which will be the first of its kind to evaluate the efficacy of CBCT-CP + for Veterans with CP and psychological comorbidity (PTSD and/or depression). Specifically, this study was motivated by the need for fully powered, adequately controlled clinical trials of novel interventions for CP with psychological comorbidities (PTSD and/or depression). We anticipate that CBCT-CP + will be superior to health and wellness psychoeducation control in improving pain-related functioning and decreasing severity of comorbid psychopathology among Veterans, which could ultimately improve care for Veterans and ameliorate serious concomitants including suicide and opioid misuse. The present study could pave the way for subsequent multi-site efficacy trials, effectiveness/implementation trials, or additional adaptations for other populations or settings. Among Veterans with both psychiatric condition(s) and CP, addressing these inter-related problems with a CIH approach (e.g., CM-based approach) offers several clinical advantages. Compared to sequential disorder specific interventions (∼24 weeks), CBCT-CP+ is a relatively brief intervention (10 weeks) and relies on a single provider, which can create continuity, increase rapport, and reduce frustration introduced by discontinuity of care and administrative issues. In addition, addressing the CP and PTSD and/or depression comorbidity could reduce the likelihood that the untreated disorder can worsen the treated disorder. Finally, reducing wait time for referrals and waitlists for multiple disorder-specific treatments could reduce attrition and improve both patient and other stakeholder satisfaction. Furthermore, unlike extant psychotherapies (e.g., CBT), which generally focus on (disorder-specific) symptom reduction, our theoretically driven CBCT-CP + may also facilitate improvements in life satisfaction and overall well-being, above and beyond symptom reduction. In conclusion, the results of this innovative RCT could set the stage for, 1) improving concerningly high partial and non-response rates of even the most effective CP and disorder-specific psychological treatments; 2) increasing the availability of CIH approaches addressing both psychological comorbidities and chronic pain interference, which often do not improve with disorder-specific treatment; and 3) addressing the paucity of adequately-powered, well-designed, controlled trials of CIH approaches, including CM-based approaches, particularly among Veterans, which can inform subsequent research and clinical recommendations. Clinical trials registration This randomized clinical trial is registered at clinicaltrials.gov (ID: NCT04651296). Disclaimer The views expressed in this article are solely those of the authors and do not reflect an endorsement by or the views of the Department of Veterans Affairs of the U.S. Government. Funding This study was supported by grant 1IK2CX002041-01A2 from Office of Research and Development (Clinical Science Research and Development), Department of Veterans Affairs, United States. CRediT authorship contribution statement Anne Malaktaris: Conceptualization, Funding acquisition, Methodology, Supervision, Visualization, Writing – original draft, Writing – review & editing. Niloofar Afari: Conceptualization, Methodology, Resources, Supervision, Writing – review & editing. Pollyanna Casmar: Conceptualization, Methodology, Supervision, Writing – review & editing. Matthew S. Herbert: Conceptualization, Methodology, Writing – review & editing. Rachel Raver: Methodology, Writing – review & editing. Julie Kangas: Methodology, Writing – review & editing. Lin Liu: Formal analysis, Methodology, Writing – review & editing. Fadel Zeidan: Conceptualization, Methodology, Writing – review & editing. Ariel J. Lang: Conceptualization, Methodology, Resources, Supervision, Writing – review & editing. Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper. Contributor Information Anne Malaktaris, Email: anne.malaktaris@va.gov. Niloofar Afari, Email: niloofar.afari@va.gov. Pollyanna Casmar, Email: pollyanna.casmar@va.gov. Matthew S. Herbert, Email: matthew.herbert2@va.gov. Rachel Raver, Email: rachel.raver@va.gov. Julie Kangas, Email: julie.kangas@va.gov. Lin Liu, Email: l2liu@health.ucsd.edu. Fadel Zeidan, Email: fzeidan@health.ucsd.edu. Ariel J. Lang, Email: ajlang@health.ucsd.edu. Data availability Data will be made available on request. References Associated Data Data Availability Statement Data will be made available on request.